Artemisinin kinetics and dynamics during oral and rectal treatment of uncomplicated malaria*
- 3 April 1998
- journal article
- clinical trial
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 63 (4) , 482-493
- https://doi.org/10.1016/s0009-9236(98)90044-3
Abstract
To compare parasite clearance times after oral and rectal administration of artemisinin in adults with uncomplicated malaria and to relate pharmacodynamics with artemisinin kinetics and to disclose any pharmacokinetic changes during treatment.Thirty male Vietnamese patients with falciparum malaria were randomized to treatment with 500 mg artemisinin daily by either the oral or rectal route of administration. Parasite densities in capillary blood were determined by microscopy every 4 to 6 hours. Artemisinin plasma concentrations on the first and last day of treatment were determined by HPLC and unbound fractions in plasma were determined by ultrafiltration.Mean parasite clearance times and 95% confidence intervals (95% CI) were 25 (95% CI, 16 to 33) and 29 (95% CI, 23 to 35) hours during oral and rectal treatment, respectively. The bioavailability after rectal relative to oral artemisinin was 30%. Artemisinin areas under the plasma concentration-time curve (AUC) on the fifth (last) day of oral or rectal treatment were 30% (95% CI, 4% to 56%) and 40% (95% CI, -6% to 91%), respectively, of those after the first dose. The fraction unbound in plasma was 15% (95% CI, 12% to 19%), increasing marginally during treatment. No relationship was found between main clinical end points and drug exposure, although indices for the rapidity of response onset were lower after oral treatment and correlated to unbound AUC values (rS = -0.7; p < 0.001).The similarity in parasite clearance times despite lower drug levels during rectal treatment suggests that initial oral doses may be unnecessarily high. The singular time dependency of artemisinin pharmacokinetics, attributed to autoinduction of drug elimination, has possible implications for combination chemotherapy. Decreasing artemisinin concentrations during treatment may partly explain recrudescences and increase the risk for resistance development.Keywords
This publication has 24 references indexed in Scilit:
- Clinical efficacy and pharmacokinetics of artemisinin monotherapy and in combination with mefloquine in patients with falciparum malariaBritish Journal of Clinical Pharmacology, 1996
- Possible Isozyme-specific Effects of Experimental Malaria Infection with Plasmodium berghei on Cytochrome P450 Activity in Rat Liver MicrosomesJournal of Pharmacy and Pharmacology, 1994
- QinghaosuThe Lancet, 1993
- The binding of the antimalarial arteether to human plasma proteins in-vitroJournal of Pharmacy and Pharmacology, 1992
- The pharmacokinetics of artemisinin after oral, intramuscular and rectal administration to volunteersJournal of Pharmacy and Pharmacology, 1990
- HIGH RATE OF PLASMODIUM VIVAX RELAPSE FOLLOWING TREATMENT OF FALCIPARUM MALARIA IN THAILANDThe Lancet, 1987
- Qinghaosu (Artemisinin): an Antimalarial Drug from ChinaScience, 1985
- Noncompartmental Determination of the Steady-State Volume of Distribution for Any Mode of AdministrationJournal of Pharmaceutical Sciences, 1982
- The application of statistical moment theory to the evaluation ofin vivo dissolution time and absorption timeJournal of Pharmacokinetics and Biopharmaceutics, 1980